Jun 24, 2026 03:14AM
Jun 9, 2026 04:30PM
May 13, 2026 05:46AM
Apr 8, 2026 09:35AM
Mar 30, 2026 04:21AM
Mar 23, 2026 09:34AM
Mar 2, 2026 06:01AM FDA accepts rusfertide application with priority review for blood disorder
Feb 10, 2026 04:50AM
Jan 22, 2026 07:45AM
Jan 15, 2026 07:52AM
Jan 13, 2026 07:47AM
Jan 5, 2026 07:03AM
Dec 8, 2025 02:54AM
Nov 7, 2025 11:01AM Takeda reports sustained kidney function benefits 18 months after treatment
Nov 5, 2025 08:03AM
Oct 30, 2025 04:11AM
Sep 19, 2025 09:14AM
Sep 16, 2025 08:02AM
Aug 21, 2025 02:53PM
Aug 8, 2025 01:18AM
Jul 30, 2025 05:14PM Takeda Pharmaceutical Company Limited (TAK) Reports Q2 EPS of JPY151.00
Jul 21, 2025 08:01AM
Jul 14, 2025 05:55AM
Jun 3, 2025 10:13AM
May 21, 2025 09:32AM
May 14, 2025 05:10PM
Apr 2, 2025 04:50AM
Mar 3, 2025 06:46AM Protagonist Therapeutics (PTGX) and Takeda (TAK) Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera
Jan 21, 2025 08:03AM
Jan 7, 2025 11:00AM
Dec 3, 2024 07:00AM
Aug 7, 2024 06:45AM
Jun 26, 2024 05:27AM
Jun 21, 2024 04:00PM
Jun 18, 2024 08:02AM Takeda (TAK) Presents Long-Term Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA
Jun 17, 2024 06:45AM
Oct 13, 2021 06:23AM

425,868 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All